1 / 36

LIVER TRANSPLANTATION

LIVER TRANSPLANTATION. Presented by SC 胡婉妍 SC 陳建嘉 Directed by VS 詹光政 R3 陳建宇. CONTENTS. Case presentation Indications of liver transplantation Contraindications Pathophysiology of end-stage liver diseases Pre-op evaluations Intra-op considerations and management. CASE PRESENTATION.

cottman
Download Presentation

LIVER TRANSPLANTATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. LIVER TRANSPLANTATION Presented by SC 胡婉妍 SC 陳建嘉 Directed by VS 詹光政 R3 陳建宇

  2. CONTENTS • Case presentation • Indications of liver transplantation • Contraindications • Pathophysiology of end-stage liver diseases • Pre-op evaluations • Intra-op considerations and management

  3. CASE PRESENTATION

  4. Brief History of Recipient • Name: 林XX • Chart no: 3280455 • Age: 34y/o • Sex: Female • Indication of liver transplantation  Hepatocellular carcinoma • Living donar: Her husband

  5. Present illness • HBV carrier for 10+yrs • 1995/12 AFP ↑ (4460) abd. ultrasound: tumor of left lobe 1996/01/22 lateral segmentectomy • Tumor recurrence  TAE were performed at 2002/03/02 2002/05/31 2002/07/25

  6. Past History • DM (-) ; HTN(-) • HBV infection with cirrhosis for 10+yrs • History of allergy: nil • Drinking or smoking: nil • Family history: non-contributory

  7. Lab Data • CBC; electrolytes: normal • Plt count: 209K • Albumin: 4.3 • Total bilirubin: 0.5 • GOT/GPT: 20/17 • PT: 12.5/10.4 • pTT: 35.7/36.4

  8. Course of Operation • OP procedures: Under ETGA ↓ Bilateral subcostal incision with extension to xyphysis ↓ Identify the liver hilum, portal v., hepatic a. and v. ↓ Cholecystectomy & CBD ligation ↓ Hepatic a. ligation ↓ Clamp portal v. & hepatic v. when donar liver was well prepared ↓

  9. Remove liver ↓ Connect portal v.  hepatic v.  hepatic a. by plastic surgeon ↓ Connect CBD to hepatic duct ↓ Irrigation with warm N/S and wound closure

  10. DISCUSSION

  11. Fulminant hepatic failure Viral hepatitis Drug-induced Metabolic (eg. Reye’s syndrome) End-stage chronic liver disease Chronic viral Primary biliary cirrhosis Primary sclerosing cholangitis Biliary atresia Vascular disease ( Budd-Chiari syndrome) Veno-occlusive disease Idiopathic autoimmune Alcoholic Metabolic liver diseases Wilson’s disease Hematochromatosis Glycogen storage disease Α1-antitrypsin deficiency Nonresectable hepatic malignancies Cholangiocarcinoma HCC Indications of Liver Transplantation • 1. Solitary tumor< 5cm • ≤ 3 lesions with the • diameter of the largest • tumor ≤ 3cm

  12. Contraindications • AIDS • Extrahepatic malignancy • Uncontrolled sepsis • Active alcoholism or substance abuse • Fulminant hepatic failure with sustained ICP > 50 mm Hg or CPP < 40 mm Hg • Advanced cardiac or pulmonary disease • Child-Turcotte-Pugh score < 7 • HLA incompatibility?

  13. Preanesthetic Considerations for End-Stage Liver Diseases • Encephalopathy • ICP monitor; TCD • hyperventilation

  14. Circulation Intravascular volume depletion SVR↓; CO↑; normal~low BP Epinephrine & norepinephrine (starting dose 0.1μg/kg/min) Prostacyclin

  15. Pulmonary functions Atelectasis from abdominal distention and ascites Pleural effusions hepatopulmonary syndrome clinical triad:1. advanced chronic liver disease; 2. severe arterial hypoxemia; 3. intrapulmonary vascular dilatations ~Rodriguez-Roisin R, Agusti AGN, Roca J; Thorax 47:897-902, 1992.

  16. Renal dysfunction intravascular volume depletion hepatorenal syndrome Plasma volume expansion (colloid) Renal dose dopamine (3μg/kg/min) Lasix infusion at 10~50mg/h

  17. Metabolic manifestations Diminished albumin synthesis narcotics & barbituates chronic hypoglycemia coagulopathy thrombocytopenia reduced hepatic clearance of fibrinolysins and tPA

  18. Monitor & Induction • Invasive monitoring with systemic and PA catheters • Radial and femoral artery catheters • End-tidal CO2 • Urine output • Temperature • Aspiration precautions

  19. IV anesthetics Thiopental, etomidate, propofol, ketamine, succinylcholine Plasma pseudocholinesterase levels Thiopental Inhalational anesthetics contraindicated in patients with IICP Nitrous oxide isoflurane Muscle relaxants Highly water soluble Atracurium; cisatracurium Ref: Mosby: Principle & Practice of Anesthesiology 2nd ed. Miller:Anesthesia; 5th ed.

  20. Operation Preanhepatic phase Anhepatic phase Neohepatic phase

  21. Preanhepatic Phase

  22. Physiological alterations in preanhepatic phase • Hemorrhage • Acute decompression of ascites • Coagulation and metabolic derangements • Citrate-induced hypocalcemia • Oliguria

  23. Management • Close monitoring • Fluid, blood and FFP transfusion • Calcium infusion • Correction of metabolic acidosis • Diuretics and renal-dose dopamine

  24. In our patient… • Hemodynamic status • Metabolic change • Coagulation function • Electrolyte level • Urine output • Management

  25. Anhepatic Phase

  26. Physiological alterations in anhepatic phase • Obstruction of venous return (lower body, bowel and kidneys) • Increased metabolic alterations (absence of the liver’s metabolic functions) -> acidosis, hypocalcemia… • Atelectasis (retraction on diaphragm) • Decreased endogenous glucose production

  27. Management • Fluid loading and small dose of vasoconstrictors • Correction of metabolic acidosis • Calcium infusion • PEEP and inspiratory pressure↑ • Glucose infusion

  28. In our patient… • Hemodynamic status • Metabolic change • Coagulation function • Electrolyte and glucose level • Urine output • Management

  29. Neohepatic Phase

  30. Physiological alterations in neohepatic phase • Hypotension: cardiac output↑, systemic vascular resistance↓ • Large load of potassium, metabolic acid and endotoxin • Oxygen consumption and CO2 elimination↑ • Post-reperfusion foagulopathy

  31. Management • Vasoconstrictors and inotropic support • Preflushing of the portal vein and liver • Correct metabolic acidosis and electrolyte imbalance • Potamine sulfate

  32. In our patient… • Hemodynamic status • Metabolic change • Coagulation function • Electrolyte level • Urine output • Management

  33. Conclusion Anhepatic phase Neohepatic phase Preanhepatic phase

  34. Thanks for your attention!

More Related